Thanks for subscribing!
- 1st Patient Enrolled in Phase 1 Trial of Antibody Therapy BHV-1100
- Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial
- Blenrep-nirogacestat Combo Moves to Dose-testing Phase 2 of Trial
- FDA Expects Decision on Cilta-cel Approval by February 2022
- Xpovio Open to Advanced Myeloma Patients Outside US via Access Program